Hemophilia A Market to Grow Positively at a Paltry CAGR During the Study Period, DelveInsight | BioMarin Pharmaceutical, Roche (Spark Therapeutics), ApcinteX, Novo Nordisk, Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Sangamo Therapeutics, Bayer, Ul

DelveInsight's "Hemophilia A - Market Insight, Epidemiology and Market Forecast - 2034" report provides current treatment practices, emerging drugs, Hemophilia A market share of the individual therapies, current and forecasted Hemophilia A market size from 2020 to 2034 segmented by seven major markets. The report also offers current Hemophilia A therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Hemophilia A market.
Request for a detailed sample report @ https://www.delveinsight.com/report-store/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key highlights from the Hemophilia A Market Report:
In 2023, the Hemophilia A market was the largest in the US among the 7MM, with a market size of approximately USD 5,000 million, and is projected to grow further by 2034.
In September 2023, concizumab was approved in Japan under the brand name ALHEMO for treating hemophilia A and B with inhibitors. Novo Nordisk plans to launch ALHEMO in Japan in the first half of 2024.
In June 2023, the US FDA approved ROCTAVIAN by BioMarin Pharmaceutical for adults with severe hemophilia A, provided they have no pre-existing antibodies to adeno-associated virus serotype 5 as detected by an FDA-approved test. BioMarin Pharmaceutical reported treating the first commercial patient with ROCTAVIAN in Germany during Q3 2023, followed by a second patient in November 2023.
Sanofi is preparing to submit fitusiran for hemophilia A and B in 2024, with a later submission planned for pediatric cases of hemophilia A and B in 2025 or beyond.
The emerging Hemophilia A pipeline includes several promising drugs in late and early stages of development (Phase III and I/II), such as dirloctocogene samoparvovec (RG6357 or SPK-8011), fitusiran (ALN-AT3, SAR-439774), and marstacimab (PF-06741086), which have the potential to significantly impact the Hemophilia A market during the forecast period.
Key hemophilia A companies working in the market are BioMarin Pharmaceutical, Roche (Spark Therapeutics), ApcinteX, Novo Nordisk, Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Sangamo Therapeutics, Bayer, Ultragenyx Pharmaceutical, and others.
Hemophilia A Overview
Hemophilia A is a genetic bleeding disorder characterized by a deficiency or absence of clotting factor VIII. Historically, treatment for this condition involved FVIII replacement therapy, starting with whole blood donations, progressing to plasma, and now utilizing recombinant human FVIII (rFVIII) therapies, which have significantly advanced the management of the disorder. While hemophilia is typically diagnosed at birth, it can occasionally develop later in life if the body begins to produce antibodies that attack clotting factors, though this acquired form is very rare.

The severity of Hemophilia A varies among individuals, ranging from mild to severe. Symptoms and bleeding frequency often depend on the levels of factor VIII and the blood's overall clotting ability. Generally, bleeding episodes are more common during childhood and adolescence than in adulthood, regardless of the disorder's severity.

Diagnosis of Hemophilia A involves assessing characteristic symptoms, detailed patient history, clinical evaluation, and various specialized laboratory tests. Confirming the diagnosis typically requires identifying a hemizygous F8 pathogenic variant through molecular genetic testing in a male patient.

Approximately 30% of patients with severe Hemophilia A develop neutralizing anti-FVIII alloantibodies (inhibitors) that render FVIII replacement therapies ineffective. For these patients, the standard treatment involves inducing immune tolerance with high-dose, high-frequency FVIII and using bypassing agents like recombinant activated factor VII (e.g., NOVOSEVEN, FEIBA). Several approved therapies are available for managing Hemophilia A, including ALTUVIIIO, ROCTAVIAN, HEMLIBRA, ALHEMO, among others.
To know more about hemophilia A, visit: https://www.delveinsight.com/report-store/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Hemophilia A Epidemiological Insights
In 2023, the United States had a prevalent population of nearly 14,300 individuals with Hemophilia A, representing about 30% of the total prevalence across the 7MM.
Among the EU4 countries and the UK, France reported the highest number of diagnosed cases of Hemophilia A, followed by the UK. Spain had the fewest cases in 2023.
In Japan, the prevalent population of Hemophilia A was approximately 5,600 in 2023 and is expected to grow during the forecast period.
In the United States, the distribution of Hemophilia A cases in 2023 was as follows: approximately 3,600 cases were classified as mild, about 2,900 as moderate, and around 7,900 as severe.

Hemophilia A Treatment Market
The Hemophilia A market features a range of recombinant factor VIII (FVIII) products, including both third-generation and second-generation recombinants, as well as plasma-derived clotting factors. Despite the availability of these treatments, none offer a complete cure or full management of the condition.

HEMLIBRA, developed by Genentech/Chugai/Roche, is a bispecific antibody first approved in 2017 for patients with Hemophilia A and FVIII inhibitors. In 2018, it received approval for routine prophylaxis in patients with Hemophilia A, both with and without FVIII inhibitors, in the US, Europe, and Japan.

In early 2023, the FDA approved ALTUVIIIO for routine prophylaxis, on-demand treatment, and perioperative management in both adults and children with Hemophilia A. Later that year, ROCTAVIAN, a gene therapy for severe Hemophilia A without pre-existing antibodies to adeno-associated virus serotype 5, also received FDA approval. ROCTAVIAN has demonstrated better efficacy and safety compared to HEMLIBRA.

The current treatment landscape is primarily driven by non-inhibitor drug candidates, but ongoing research and development by companies such as Novo Nordisk, Sanofi, Pfizer/Sangamo, and Roche/Spark Therapeutics are focused on innovative therapies that could potentially transform the management of Hemophilia A and offer new possibilities for a cure.
Promising Therapies in the Hemophilia A Pipeline
Concizumab
Fitusiran
BIVV001
Marstacimab
Valrox
And others
Discover more about Hemophilia A therapies in the pipeline @ https://www.delveinsight.com/sample-request/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Leading Companies Working in the Hemophilia A Market
Novo Nordisk
Sanofi
Sanofi in collaboration with Sobi
Pfizer
BioMarin Pharmaceutical
And others
To understand key companies related to the Hemophilia A Market, get a snapshot of the Hemophilia A Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/hemophilia-a2030-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Hemophilia A Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Hemophilia A Companies: Novo Nordisk, Sanofi, Sanofi in collaboration with Sobi, Pfizer, BioMarin Pharmaceutical, and others
Key Hemophilia A Pipeline Therapies: Concizumab, Fitusiran, BIVV001, Marstacimab, Valrox, and others
Therapeutic Assessment: Hemophilia A current marketed and emerging therapies
Hemophilia A Market Dynamics: Hemophilia A market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Hemophilia A Market Access and Reimbursement
Table of Contents
1. Hemophilia A Market Key Insights
2. Hemophilia A Market Report Introduction
3. Hemophilia A Market Overview at a Glance
4. Hemophilia A Market Executive Summary
5. Disease Background and Overview
6. Hemophilia A Treatment and Management
7. Hemophilia A Epidemiology and Patient Population
8. Patient Journey
9. Hemophilia A Emerging Drugs
10. 7MM Hemophilia A Market Analysis
11. Hemophilia A Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Hemophilia A Market Drivers
15. Hemophilia A Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports By DelveInsight:

Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market

Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.